Veerhealth Care Limited has secured a repeat order worth ₹3.60 crores from a leading FMCG company for the supply of face care products. The order, announced on June 10, 2026, is scheduled for execution within 45 days. This contract reinforces the company's position in the skincare segment and contributes to its revenue targets for the financial year.

The buyer is a leading FMCG company operating in domestic and international markets within the 'personal and household care' segment. This entity is part of a 125-year-old prominent business group. Veerhealth Care clarified that the promoter, promoter group, or group companies hold no interest in the awarding entity, and the transaction does not fall within related party transactions.

Order Details

Financial Outlook

For FY 2026-27, Veerhealth Care expects total revenues of ₹70-75 crores with a PAT of 7-10%. The company stated that considering the current order book and ongoing discussions for orders with domestic and export buyers, it may exceed this revenue projection. Additionally, the company anticipates reaching a revenue of ₹100 crores with a PAT of 10% within the next 24 months.

Veerhealth Care Limited specializes in manufacturing pure vegetarian toothpaste and operates under the Ayuveer brand. The company highlighted that very few small-cap companies globally have secured USFDA plant clearance, positioning it in a distinctive category.

Veerhealth Care Limited reported a total income of ₹33.29 crore for the financial year ended March 31, 2026, representing a year-on-year growth of 86.08%. The company's net profit for FY26 stood at ₹0.54 crore, an increase of 38.46% compared to the previous year, while EBITDA rose 82.68% to ₹3.27 crore. The growth was driven by the company's focus on expanding its international footprint and strengthening its domestic presence, alongside the addition of new product categories.

The standalone financial results were published in Active Times Newspaper and Mumbai Lakshadeep Newspaper on June 1, 2026, under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. For the quarter ended March 31, 2026, the company reported a net loss of ₹35.37 lakh, contrasting with a profit of ₹40.48 lakh in the preceding quarter ended December 31, 2025. This quarterly decline was attributed to a forex loss of ₹0.31 crore classified as exceptional items and a provision of ₹0.49 crore for deferred tax.

Financial Performance

The company's net worth as of March 31, 2026, stood at ₹2292.32 lakh, compared to ₹2221.88 lakh in the previous year. Earnings per share (EPS) for the full year improved to ₹0.27 from ₹0.20 in FY25. The EBITDA margin for FY26 was 9.82%, a year-on-year decline of 18 basis points, while the net profit margin was 1.62%, a decline of 56 basis points.

Assets and Liabilities

The company's total assets increased to ₹4417.44 lakh as of March 31, 2026, from ₹3377.01 lakh a year ago. Current assets rose significantly to ₹1847.59 lakh, primarily due to higher trade receivables and inventories. Total equity and liabilities also grew to ₹4417.44 lakh, with total current liabilities reaching ₹1344.61 lakh.

Strategic Developments

During FY26, Veerhealth Care announced orders totaling ₹16.51 crore from various markets, including exports to the USA and domestic marketplaces. The company completed the onboarding of its Ayurveer products on Myntra, expanding its e-commerce presence across platforms such as Amazon, Flipkart, Nykaa, Glowroad, and Jiomart. Additionally, production commenced at a new facility featuring in-house plastic molding for packaging and backward integration.

Looking ahead, the company expects total revenues of ₹70-75 crore with a PAT of 7-10% in FY27. Veerhealth Care aims to reach revenues of ₹100 crore with a PAT of 10% within the next 24 months, supported by ongoing discussions for exports to Russia and scaling operations in the U.S. market.

Board Appointments

The Board of Directors appointed M/s. Vivek P. Joisar & Co., Chartered Accountants, as the Internal Auditor of the company for the financial year 2026-2027. The firm, registered with Firm Registration No. 144543W, brings over five years of combined experience in finance, auditing, taxation, and transaction advisory services. This appointment was made in compliance with Regulation 30 and Part-A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Auditor's Report

M/s. Jayesh R. Shah & Co., Statutory Auditors, issued an unmodified opinion on the standalone financial results. The auditors confirmed that the results are presented in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provide a true and fair view of the company's financial performance.